Klinikum Hochsauerland GmbH

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Myelodysplastic syndromes3 trials
• Acute myeloid leukaemia2 trials
• Multiple myeloma2 trials
• Acute lymphoblastic leukaemia1 trial
• Colorectal cancer1 trial

Phase

• Phase 34 trials
• Phase 23 trials

Status

• Recruiting4 trials
• Active, not recruiting3 trials
• Completed1 trial

Lead sponsor

• Dominik Paul Modest1 trial
• Goethe University1 trial
• Stichting Hemato-Oncologie voor Volwassenen Nederland1 trial
• Universitaet Leipzig1 trial
• Universitaetsklinikum Heidelberg AöR1 trial
• and 3 more

Running trials

• Not yet recruiting

  Pre-Operative Treatment in REseCTable COlon CanceR

  NCT06899477· Phase 3· Dominik Paul Modest· Source

• Recruiting

  A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma (GMMG-HD9/DSMM XVIII-trial)

  2023-507402-13-00· Phase 3· Universitaetsklinikum Heidelberg AöR· Source

• Recruiting

  Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT

  NCT06061094· Phase 2· Goethe University· Source

• Recruiting

  Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions

  NCT05384691· Phase 2· University of Leipzig· Source

  Contact: Anne Sophie Kubasch, Dr.

• Active, not recruiting

  A phase II, open-label, single arm study to evaluate the efficacy of Luspatercept in Erythropoiesis-stimulating agent naive lower-risk MDS patients with or without ring sideroblasts who do not require RBC transfusions

  2024-516438-36-00· Phase 2· Universitaet Leipzig· Source

• Active, not recruiting

  A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

  NCT04027309· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Recruiting

  Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project

  NCT01252485· University of Ulm· Source

  Contact: Mohammad Wattad, Dr.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• Colorectal cancer1 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Active, not recruiting

  Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

  NCT06216158· Phase 3· University of Heidelberg Medical Center· Source